Background and study aims: Pancreatitis complicates 1 % - 22 % of endoscopic retrograde cholangiopancreatography
procedures. The study aims were to develop a reproducible animal model of post-ERCP
pancreatitis (PEP), and investigate the impact of endoscopic technique on severity
of PEP.
Patients and methods: ERCP was carried out in six male hound dogs. Pancreatitis was induced by one
of three escalating methods: 1) pancreatic acinarization with 20 - 30 mL of
contrast; 2) acinarization + ductal balloon occlusion + sphincterotomy; 3) acinarization
+ intraductal synthetic bile injection + ductal balloon occlusion + sphincterotomy.
Dogs 5 and 6 received a pancreatic stent. Necropsy was performed on postoperative
day 5. All pancreatic specimens were graded by two blinded pathologists according
to a validated scoring system. All dogs were compared with three control dogs.
Results: Dogs 1 - 4 developed clinical pancreatitis and hyperamylasemia (11 736 vs. 722
U/L, P = 0.02). Total injury scores were significantly elevated compared with controls
(6.85 vs. 1.06, P = 0.004). There was significant increase in acinar cell necrosis (0.86 vs. 0.06,
P = < 0.001), and all other categories (except fibrosis) demonstrated elevated injury
scores. Dogs 5 and 6 developed clinical pancreatitis without significant hyperamylasemia;
total injury scores were elevated compared with controls (4.83 vs. 1.06, P = 0.01), but lower than in Dogs 1 - 4 (4.83 vs. 6.85, P = 0.25). There was escalating severity of pancreatic injury from Dogs 1 to 4 correlating
with the method of endoscopic injury used.
Conclusion: Severity of PEP is directly proportional to invasiveness of endoscopic intervention.
Pancreatic acinarization, even without balloon occlusion and sphincterotomy, can
be used as a reliable animal model for future studies investigating therapy and
prevention of disease.
References
1
Marks J M, Dunkin B J, Shillingstad B L. et al .
Pretreatment with allopurinol diminishes pancreatography-induced pancreatitis
in a canine model.
Gastrointest Endosc.
1998;
48
180-183
2
Freeman M L, Nelson D B, Sherman S. et al .
Complications of endoscopic biliary sphincterotomy.
N Engl J Med.
1996;
335
909-918
3
Bilbao M K, Dotter C T, Lee T G. et al .
Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study
of 10,000 cases.
Gastroenterology.
1976;
70
314-320
4
Freeman M L, Guda N M.
Prevention of post-ERCP pancreatitis: a comprehensive review.
Gastrointest Endosc.
2004;
59
845-864
5
Pfau P R, Mosley R G, Said A. et al .
Comparison of the effect of non-ionic and ionic contrast agents on pancreatic
histology in a canine model.
JOP.
2006;
7
27-33
6
Cotton P B, Lehman G, Vennes J. et al .
Endoscopic sphincterotomy complications and their management: an attempt at
consensus.
Gastrointest Endosc.
1999;
37
383-393
7
Cheng C L, Sherman S, Watkins J L. et al .
Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Am J Gastroenterol.
2006;
101
139-147
8
Testoni P A.
Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis:
a never-ending story.
Gastrointest Endosc.
2006;
64
732-734
9
Cavallini G, Tittobello A, Frulloni L. et al .
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde
cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group.
N Engl J Med.
1996;
335
919-923
10
Katsinelos P, Kountouras J, Chatzis J. et al .
High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective
randomized double-blind controlled trial.
Gastrointest Endosc.
2005;
61
407-415
11
Murray B, Carter R, Imrie C. et al .
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde
cholangiopancreatography.
Gastroenterology.
2003;
124
1786-1791
12
Deviere J, Le Moine O, Van Laethem J L. et al .
Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic
retrograde cholangiopancreatography.
Gastroenterology.
2001;
120
498-505
13
Sudhindran S, Bromwich E, Edwards P R.
Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate
in endoscopic retrograde cholangiopancreatography-induced pancreatitis.
Br J Surg.
2001;
88
1178-1782
14
Raty S, Sand J, Pulkkinen M. et al .
Post-ERCP pancreatitis: reduction by routine antibiotics.
J Gastrointest Surg.
2001;
5
339-345
15
Moreto M, Zaballa M, Casado I. et al .
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a
randomized double-blind trial.
Gastrointest Endosc.
2003;
57
1-7
16
Binmoeller K F, Harris A G, Dumas R. et al .
Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?.
Gut.
1992;
33
1129-1133
17
Prat F, Amaris J, Ducot B. et al .
Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind
randomized study.
Gastrointest Endosc.
2002;
56
202-208
18
Sand J, Nordback I.
Prospective randomized trial of the effect of nifedipine on pancreatic irritation
after endoscopic retrograde cholangiopancreatography.
Digestion.
1993;
54
105-111
19
Schwartz J J, Lew R J, Ahmad N A. et al .
The effect of lidocaine sprayed on the major duodenal papilla on the frequency
of post-ERCP pancreatitis.
Gastrointest Endosc.
2004;
59
179-184
20
Cunliffe W J, Cobden I, Lavelle M I. et al .
A randomised, prospective study comparing two contrast media in ERCP.
Endoscopy.
1987;
19
201-202
21
Hannigan B F, Keeling P W, Slavin B. et al .
Hyperamylasemia after ERCP with ionic and non-ionic contrast media.
Gastrointest Endosc.
1985;
31
109-110
22
Johnson G K, Geenen J E, Bedford R A. et al .
A comparison of nonionic versus ionic contrast media: results of a prospective,
multicenter study. Midwest Pancreaticobiliary Study Group.
Gastrointest Endosc.
1995;
42
312-316
23
O’Connor H J, Ellis W R, Manning A P. et al .
Iopamidol as contrast medium in endoscopic retrograde pancreatography: a prospective
randomised comparison with diatrizoate.
Endoscopy.
1988;
20
244-247
24
Sherman S, Hawes R H, Rathgaber S W. et al .
Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality
contrast agent.
Gastrointest Endosc.
1994;
40
422-427
25
Weiner G R, Geenen J E, Hogan W J. et al .
Use of corticosteroids in the prevention of post-ERCP pancreatitis.
Gastrointest Endosc.
1995;
42
579-583
26
Budzynska A, Marek T, Nowak A. et al .
A prospective, randomized, placebo-controlled trial of prednisone and allopurinol
in the prevention of ERCP-induced pancreatitis.
Endoscopy.
2001;
33
766-772
27
De Palma G D, Catanzano C.
Use of corticosteroids in the prevention of post-ERCP pancreatitis: results
of a controlled prospective study.
Am J Gastroenterol.
1999;
94
982-985
28
Dumot J A, Conwell D L, O’Connor J B. et al .
Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a
randomized, multicenter, placebo-controlled clinical trial.
Am J Gastroenterol.
1998;
93
61-65
29
Sherman S, Blaut U, Watkins J L. et al .
Does prophylactic administration of corticosteroid reduce the risk and severity
of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
Gastrointest Endosc.
2003;
58
23-29
30
Manolakopoulos S, Avgerinos A, Vlachogiannakos J. et al .
Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP
pancreatitis: a multicenter randomized controlled trial.
Gastrointest Endosc.
2002;
55
470-475
31
Rongione A J, Kusske A M, Kwan K. et al .
Interleukin 10 reduces the severity of acute pancreatitis in rats.
Gastroenterology.
1997;
112
960-967
32
Van Laethem J L, Marchant A, Delvaux A. et al .
Interleukin 10 prevents necrosis in murine experimental acute pancreatitis.
Gastroenterology.
1995;
108
1917-1922
33
Dumot J A, Conwell D L, Zuccaro G. et al .
A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced
pancreatitis.
Am J Gastroenterol.
2001;
96
2098-2102
34
Rabenstein T, Roggenbuck S, Framke B. et al .
Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis
after ERCP?.
Gastrointest Endosc.
2002;
55
476-483
35
Masci E, Cavallini G, Mariani A. et al .
Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP
pancreatitis.
Am J Gastroenterol.
2003;
98
2182-2186
36
Andriulli A, Leandro G, Niro G. et al .
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Gastrointest Endosc.
2000;
51
1-7
37
Arvanitidis D, Anagnostopoulos G K, Giannopoulos D. et al .
Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled
trial.
J Gastroenterol Hepatol.
2004;
19
278-282
38
Bordas J M, Toledo-Pimentel V, Llach J. et al .
Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography:
results of a randomized study.
Gastrointest Endosc.
1998;
47
230-234
39
Poon R T, Yeung C, Lo C M. et al .
Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized
controlled trial.
Gastrointest Endosc.
1999;
49
593-598
40
Sternlieb J M, Aronchick C A, Retig J N. et al .
A multicenter, randomized, controlled trial to evaluate the effect of prophylactic
octreotide on ERCP-induced pancreatitis.
Am J Gastroenterol.
1992;
87
1561-1566
41
Testoni P A, Bagnolo F, Andriulli A. et al .
Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis:
results of a multicenter, randomized, controlled trial.
Aliment Pharmacol Ther.
2001;
15
965-972
42
Qin H L, Su Z D, Gao Q. et al .
Early intrajejunal nutrition: bacterial translocation and gut barrier function
of severe acute pancreatitis in dogs.
Hepatobiliary Pancreat Dis Int.
2002;
1
150-154
43
Chen J, Wang X P, Liu P. et al .
Effects of continuous early enteral nutrition on the gut barrier function in
dogs with acute necrotizing pancreatitis.
Zhonghua Yi Xue Za Zhi.
2004;
84
1726-1731
44
Zhu Q, Yuan Y, Xia L. et al .
The effect of sandostatin on sphincter of Oddi in acute severe pancreatitis
in dogs.
Zhonghua Nei Ke Za Zhi.
1999;
38
747-749
45
Boerma D, Straatsburg I H, Offerhaus G J. et al .
Experimental model of obstructive chronic pancreatitis in pigs.
Dig Surg.
2003;
20
520-526
46 Evans H E.
The digestive apparatus and abdomen. In: Miller’s anatomy of the dog. 2nd edn. Philadelphia; Saunders 1983: 456-460
47
Newman S J, Steiner J M, Woosley K. et al .
Histologic assessment and grading of the exocrine pancreas in the dog.
J Vet Diagn Invest.
2006;
18
115-118
48
Tarnasky P R, Palesch Y Y, Cunningham J T. et al .
Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients
with sphincter of Oddi dysfunction.
Gastroenterology.
1998;
115
1518-1524
49
Tarnasky P R.
Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: results,
techniques, and indications.
JOP.
2003;
4
58-67
50
Pezzilli R, Venturi M, Morselli-Labate A M. et al .
Serum trypsinogen activation peptide in the assessment of the diagnosis and
severity of acute pancreatic damage: a pilot study using a new determination
technique.
Pancreas.
2004;
29
298-305
J. M. Buscaglia, MD
Johns Hopkins Hospital
1830 E. Monument Street
Room 7100-A
Baltimore MD 21205
USA
Fax: +1-410-955-2108
eMail: jbuscaglia@jhmi.edu